Polydex Pharmaceuticals Stock Debt To Equity
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Polydex Pharmaceuticals fundamentals help investors to digest information that contributes to Polydex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Polydex Pink Sheet. The fundamental analysis module provides a way to measure Polydex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Polydex Pharmaceuticals pink sheet.
Polydex |
Polydex Pharmaceuticals Company Debt To Equity Analysis
Polydex Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Polydex Pharmaceuticals Debt To Equity | 0.05 % |
Most of Polydex Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Polydex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Polydex Pharmaceuticals has a Debt To Equity of 0.053%. This is 99.9% lower than that of the Pharmaceuticals sector and 99.73% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.89% higher than that of the company.
Polydex Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Polydex Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Polydex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Polydex Pharmaceuticals by comparing valuation metrics of similar companies.Polydex Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Polydex Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 | |||
| Profit Margin | (0.25) % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 3.43 M | |||
| Number Of Shares Shorted | 11 | |||
| Price To Earning | 12.33 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 4.05 M | |||
| Gross Profit | 970.3 K | |||
| EBITDA | (568.16 K) | |||
| Cash And Equivalents | 870.3 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 301.49 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 5.88 X | |||
| Book Value Per Share | 1.44 X | |||
| Cash Flow From Operations | (238.54 K) | |||
| Short Ratio | 0.02 X | |||
| Earnings Per Share | (0.13) X | |||
| Number Of Employees | 21 | |||
| Beta | 0.33 | |||
| Market Capitalization | 2.23 M | |||
| Total Asset | 6.56 M | |||
| Retained Earnings | (19.53 M) | |||
| Working Capital | 2.12 M | |||
| Current Asset | 3.41 M | |||
| Current Liabilities | 1.28 M | |||
| Z Score | 1.4 |
About Polydex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Polydex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Polydex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Polydex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |